LEXXW News and Press, Lexaria Bioscience Corp. Warrant From 06/21/22

(TheNewswire) Expands DehydraTECH™ B2B manufacturing capabilities to support Lexaria’s growing corporate customer base Lexaria to also receive royalty revenue from DehydraTECH product sales through BevNology’s commercial license rig...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced the awarding of a five-year, non-exclusive DehydraTECH(TM) license from its wholly-owned subsidiary, Lexaria Pharmaceutical Corp., to AnodGen Bioceuticals of Ireland. According to the u...

DehydraTECH Pharmaceutical License Issued for the European, Australian and New Zealand markets Lexaria to receive royalty revenue from DehydraTECH product sales KELOWNA, BC / ACCESSWIRE / June 8, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexar...

KELOWNA, BC / ACCESSWIRE / June 6, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce it has successfully filed a pre-Investigational New Drug ("IND") meeting request letter with the U...

(TheNewswire) Minimum payments due to Lexaria of US$4,527,500 over the first five years to retain exclusivity Lexaria to receive royalty revenue from DehydraTECH product sales Kelowna, British Columbia – TheNewswire - June 2, ...

KELOWNA, BC / ACCESSWIRE / June 1, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the results of the 2022 Annual Meeting (the "Meeting"). On May 31, 2022 at 1:00 p.m. (Pacific Time), the Compa...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced its receipt of its first-ever patent for the use of DehydraTECH technology in the enhanced delivery of antiviral drugs. According to the update, Lexaria has received notification from t...

(TheNewswire) 25 th patent grant is Lexaria’s first-ever patent for the enhanced delivery of antivirals Kelowna, British Columbia – TheNewswire - April 21, 2022 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasda...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced that it has begun its multi-week human clinical hypertension study. The randomized, double blinded, placebo-controlled, cross-over study in 60 people, HYPER-H21-4, is the most comprehen...

(TheNewswire) HYPER-H21-4 will evaluate DehydraTECH TM -CBD for reducing blood pressure together with other potential clinical benefits This s tudy is designed to enhance Lexaria’s probabilities of success with its ...